Search

Search Results

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1590

  PDF: 1592

  HTML: 730

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  1822

  PDF: 813

  HTML: 1216

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  3952

  PDF: 1511

  HTML: 798

• PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics

  Xiaoqiang Zheng, Hongbing Rui, Ying Liu, Jinfeng Dong

  e2020073

  2020-11-02

  https://doi.org/10.4084/mjhid.2020.073

  670

  PDF: 53

  HTML: 126

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  3967

  PDF: 1100

  HTML: 1913

  Fig.1: 202

  Fig. 2: 101

  Table 1: 183

  Table2: 198

  Table 3: 178

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3602

  PDF: 1009

  HTML: 1778

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4363

  PDF: 1292

  HTML: 2138

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  3666

  PDF: 3021

  HTML: 181

• PATHOBIOLOGY OF HODGKIN LYMPHOMA

  Claudio Agostinelli, Stefano Pileri

  e2014040

  2014-06-05

  https://doi.org/10.4084/mjhid.2014.040

  3089

  PDF: 1371

  HTML: 5830

  Fig1-Ag-Pil: 191

  Ag-Pil Fig.2: 194

• USP9X INCREASED TUMOR ANGIOGENESIS IN MANTLE CELL LYMPHOMA BY UPREGULATION OF CCND1- MEDIATED SOX11

  Gang Huang, Jianjun Liao, Mingli Wang, Yali Huang, Mingjie Tang, Yanyan Hao

  e2022048

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.048

  733

  PDF: 626

  HTML: 192

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4277

  PDF: 1562

  HTML: 3350

  Tables and Images: 194

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  1864

  PDF: 1323

  HTML: 244

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1205

  HTML: 281

  PDF: 891

  Suppl. Files: 431

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4224

  PDF: 1444

  HTML: 1528

  Untitled: 207

• HHVs AND LYMPHOPROLIFERATIVE DISORDERS

  C Quadrelli, P Barozzi, G Riva, Mario Luppi

  e2011043

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.043

  1318

  PDF: 783

  HTML: 3100

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3291

  PDF: 1239

  HTML: 2187

  Fi.1 Gritti.Rambaldi: 182

• INTEGRATION OF CD200, CD43 AND ROR1 IN MULTIPARAMETER FLOW CYTOMETRY (MFC) ROUTINE PANELS FOR THE DIFFERENTIAL DIAGNOSIS OF B-CELL LYMPHOPROLIFERATIVE DISORDERS (B-LPDS)

  Alessandro Laganà, Raffaele Maglione, Alessandro Costa, Biancamaria Mandelli, Maria Laura Bisegna, Maria Laura Milani, Valeria Filipponi, Maria Grazia Nardacci, Tania Soriano, Eugenio Santacroce, Luigi Petrucci, Carla Giordano, Maurizio Martelli, Maria Stefania De Propris

  e2025.002

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.002

  1979

  PDF: 1366

  HTML: 308

  PDF: 988

• LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B

  Eva Eliassen, Gerhard R Krueger, Mario Luppi, Dharam Ablashi

  e2018035

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.035

  3639

  PDF: 1404

  HTML: 455

  Figures . Eliassian: 198

• CIRCCTNNA1 IS UPREGULATED IN MANTLE CELL LYMPHOMA AND PREDICTS POOR SURVIVAL BY SPONGING MIR-34A TO INCREASE CELL PROLIFERATION.

  Xuebing Jing, Cong Lu, Chao Song, Qingkun Han

  e2022047

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.047

  572

  PDF: 462

  HTML: 197

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2424

  PDF: 806

  HTML: 8784

  Efremov 1: 204

  Efremov 2: 161

• COMPARATIVE EVALUATION OF BONE MARROW ASPIRATE WITH TREPHINE BIOPSY IN HEMATOLOGICAL DISORDERS AND DETERMINATION OF OPTIMUM TREPHINE LENGTH IN LYMPHOMA INFILTRATION

  Surbhi Goyal, Usha Rani Singh, Usha Rusia

  e2014002

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.002

  1827

  PDF: 1019

  HTML: 51755

• Skin Manifestations associated with Mantle cell Lymphoma: a case report

  avinash kumar singh, Gaurav Dixit, sanjeev sharma, rajni yadav, Narendra agrawaal, chitra sarkar, pravas mishra, Tulika seth, manoranjan mahapatra, Renu saxena

  e2013020

  2013-02-24

  https://doi.org/10.4084/mjhid.2013.020

  1441

  PDF: 716

  HTML: 2103

  Untitled: 175

  Untitled: 165

  Untitled: 178

  Untitled: 161

  Untitled: 177

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  2561

  PDF: 3085

  HTML: 309

• IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Alana Kennedy-Nasser, Catherine Bollard, Helen Heslop

  e2009010

  2009-11-13

  https://doi.org/10.4084/mjhid.2009.010

  1078

  PDF: 580

  HTML: 6780

• FLUDARABINE-MELPHALAN-CAMPATH FOLLOWED BY UNMANIPULATED PERIPHERAL-BLOOD HAEMATOPOIETIC STEM CELLS CAN STILL CURE LYMPHOMA.

  Daniele Avenoso, Amal Alabdulwahab, Michelle Kenyon, Varun Mehra, Pramila Krishnamurthy, Francesco Dazzi, Ye Ting Leung, Sandra Anteh, Mili Naresh Shah, Andrea Kuhnl, Robin Sanderson, Piers Patten, Deborah Yallop, Antonio Pagliuca, Victoria Potter

  e2023041

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.041

  1417

  PDF: 670

  HTML: 198

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2409

  PDF: 670

  HTML: 1504

• Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient

  Gabriele Magliano, Annarosa Cuccaro, Francesco D'Alo', Elena Maiolo, Silvia Bellesi, Stefan Hohaus, Andrea Bacigalupo, Livio Pagano

  e2021054

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.054

  1162

  PDF: 340

  HTML: 119

• IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS

  Efterpi Kostareli, Maria Gounari, Andreas Agathangelidis, Kostas Stamatopoulos

  e2012052

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.052

  2962

  PDF: 829

  HTML: 7148

  Kost Fig1: 163

  Kost Fig 2: 153

  Kost Fig3: 149

  Kost Fig 4: 166

  Kost Fig5: 162

  Kost fig 6: 149

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  1943

  PDF: 772

  HTML: 194

• Mantle cell lymphoma relapsing at the lymphedematous arm.

  Giuseppina Massini, Stefan Hohaus, Francesco D'Alo', Valentina Bozzoli, Barbara Vannata, Luigi Maria Larocca, Luciana Teofili

  e2013016

  2013-02-16

  https://doi.org/10.4084/mjhid.2013.016

  1636

  PDF: 667

  HTML: 3779

• DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Sabina Chiaretti, Gina Zini, Renato Bassan

  e2014073

  2014-10-24

  https://doi.org/10.4084/mjhid.2014.073

  8813

  PDF: 5927

  HTML: 87436

  Fig.1b: 159

  Fig.1c: 164

  Fig.2a: 154

  Fig.2b: 154

  Fig.4: 167

  Fig.2c: 152

  Fig.3: 161

  Tab.1: 208

  Tab.2: 186

  Tab.3: 175

  Tab.4: 194

  Fig1a: 151

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1917

  PDF: 1063

  HTML: 166

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2155

  PDF: 1897

  HTML: 175

• ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed L. Sorror, Rainer F. Storb

  e2010015

  2010-06-08

  https://doi.org/10.4084/mjhid.2010.015

  940

  PDF: 603

  HTML: 2198

• Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

  Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca

  e2025061

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.061

  974

  PDF: 481

  Html: 102

• GASTROINTESTINAL MYELOID SARCOMA A CASE PRESENTATION AND CRITICAL REVIEW OF THE LITERATURE GASTROINTESTINAL MYELOID SARCOMA

  Pouyan Kheirkhah, Ana M. Avila-Rodriguez, Bartlomiej Radzik, Carlos Murga-Zamalloa

  e2021067

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.067

  1139

  PDF: 561

  HTML: 190

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4228

  PDF: 1438

  HTML: 3601

• Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

  Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi

  e2026009

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.009

  473

  PDF: 316

  Html: 274